• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MET Gene Record

  • Summary
  • Interactions
  • Claims
  • MET 4233 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    4233
    MET PROTO-ONCOGENE, RECEPTOR TYROSINE KINASE
    MET
    AUTS9
    DFNB97
    HGFR
    RCCP2
    c-Met
    164860
    7029
    ENSG00000105976
    OTTHUMG00000023299
    MET_HUMAN
    P08581
    HEPATOCYTE GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (MET PROTO- ONCOGENE TYROSINE KINASE) (C-MET) (HGF RECEPTOR) (HGF-SF RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P08581]
    HEPATOCYTE GROWTH FACTOR RECEPTOR
    PA30763
    SF receptor
    HGF receptor
    Tyrosine-protein kinase Met
    Scatter factor receptor
    Proto-oncogene c-Met
    HGF/SF receptor
    52
    T40474

    Gene Info:

    Initial Gene Query MET
    Counted Citations from 1950-2000 4560
    Human Readable Name DRUGGABLE GENOME
    Human Readable Name KINASE
    Interpro Type Domain
    Uniprot Evidence 1: Evidence at protein level
    Uniprot Status Swiss-Prot
    Interpro Acc IPR001245
    Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    CancerCommons Reported Gene Name MET
    CancerCommons Reported Gene Name MET, VEGFRs, Axl, Tie2, Ron
    Target Class Receptors
    Target Subclass EC:2.7.10.1
    Gene Biotype PROTEIN_CODING
    (28 More Sources)

    Gene Categories: Category Details

    CELL SURFACE
    KINASE
    TYROSINE KINASE
    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE

    Publications:

    Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
    Patnaik et al., 2014, Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma., Br. J. Cancer
    Phillip et al., 2013, Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines., J Hematol Oncol
    Lorenzato et al., 2002, Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion., Cancer Res.
    Maulik et al., 2002, Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition., Cytokine Growth Factor Rev.
    Bardelli et al., 1998, Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth., Proc. Natl. Acad. Sci. U.S.A.
    MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn
    Olivero et al., 1999, Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family., Int. J. Cancer
    Dalinka et al., 1975, The radiology of osseous and articular infection., CRC Crit Rev Clin Radiol Nucl Med
    Zou et al., 2007, An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms., Cancer Res.
    Forde et al., 2012, Crizotinib in the treatment of non-small-cell lung cancer., Expert Opin Pharmacother
    Chu LP et al., 2019, MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel <i>MET</i> R1004G Mutation., Oncologist
    Frampton et al., 2015, Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors., Cancer Discov
    Awad et al., 2016, MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression., J. Clin. Oncol.
    Paik et al., 2015, Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping., Cancer Discov
    Togashi et al., 2015, MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor., Lung Cancer
    Bardelli et al., 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer., Cancer Discov
    Palma et al., 2014, Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary., Case Rep Oncol
    Le et al., 2015, Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling., Clin Lung Cancer
    Pietrantonio et al., 2016, MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer., Cancer Discov
    Tanizaki et al., 2011, MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations., J Thorac Oncol
    Chi et al., 2012, Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor., J. Clin. Oncol.
    Ou et al., 2011, Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification., J Thorac Oncol
    Ou SH, 2011, Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond., Drug Des Devel Ther
    Li et al., 2017, Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer., Clin. Cancer Res.
    Choi et al., 2004, Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein., Cancer Cell Int.
    Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
    Qi et al., 2011, Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors., Cancer Res.
    Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
    Shen et al., 2015, c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers., Cancer Res.
    Ou et al., 2016, High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression., Lung Cancer
    Pfefferle et al., 2016, Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers., Dis Model Mech
    Chabon et al., 2016, Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients., Nat Commun
    Secrier et al., 2016, Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance., Nat. Genet.
    Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov
    Heist et al., 2016, Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping., J Thorac Oncol
    Engstrom et al., 2017, Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models., Clin. Cancer Res.
    Lu et al., 2017, MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma., Cancer Res.
    Moro-Sibilot D et al., 2019, Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial., Ann Oncol
    Landi L et al., 2019, Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial., Clin Cancer Res
    Mahjoubi L et al., 2016, A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib., Invest New Drugs
    Drilon A et al., 2020, Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration., Nat Med
    Wiesweg M et al., 2020, Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation., Lung Cancer
    Zhu YC et al., 2018, Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing., Ann Oncol
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Choueiri et al., 2017, Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer., J. Clin. Oncol.
    Schuller et al., 2015, The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models., Clin. Cancer Res.
    Lee J et al., 2019, Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial., Cancer Discov
    Shah et al., 2017, Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial., JAMA Oncol
    Spigel et al., 2013, Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer., J. Clin. Oncol.
    Merchant et al., 2013, Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent., Proc. Natl. Acad. Sci. U.S.A.
    Catenacci et al., 2011, Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence., Cancer Discov
    Cheng et al., 2015, Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma., Cancer Res.
    Qu et al., 2014, Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models., J. Exp. Clin. Cancer Res.
    Falchook et al., 2015, Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors., Invest New Drugs
    Busnena BA et al., 2013, Olive secoiridoids and semisynthetic bioisostere analogues for the control of metastatic breast cancer., Bioorg Med Chem
    Dorsch D et al., 2015, Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors., Bioorg Med Chem Lett
    Paik PK et al., 2020, Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations., N Engl J Med
    Medová M et al., 2013, The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants., Mol Cancer Ther
    Choueiri et al., 2013, Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma., J. Clin. Oncol.
    Hudkins RL et al., 2012, Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent., J Med Chem
    Nakagawa et al., 2010, E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models., Cancer Sci.
    Minuti et al., 2012, Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer., Br. J. Cancer
    Rosen et al., 2017, A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer., Clin. Cancer Res.
    Wang et al., 2017, ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence., Clin. Cancer Res.
    Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
    Wolf J et al., 2020, Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung Cancer., N Engl J Med
    Hong JY et al., 2011, Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa., J Nat Prod
    Fujita et al., 2013, The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile., Mol. Cancer Ther.
    Egile et al., 2015, The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer., Mol. Cancer Ther.
    Yamaoka et al., 2016, Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation., Mol. Cancer Ther.
    Shien et al., 2013, Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells., Cancer Res.
    Rho et al., 2014, MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation., Cancer Res.
    Engelman et al., 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling., Science
    Zhang D et al., 2013, Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors., Bioorg Med Chem
    Smith et al., 2015, Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2., Mol. Cancer Ther.
    Piao et al., 2016, Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models., Neuro-oncology
    Kwon et al., 2015, Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment., Oncogene
    McDermott U et al., 2007, Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling., Proc Natl Acad Sci U S A
    Ortiz-Cuaran et al., 2016, Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors., Clin. Cancer Res.
    Ninomiya K et al., 2018, MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib., Sci Rep
    Dai et al., 2012, Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation., Clin. Exp. Metastasis
    Dai et al., 2010, BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro., Mol. Cancer Ther.
    Hugo et al., 2015, Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance., Cell
    Dabir et al., 2014, RET mutation and expression in small-cell lung cancer., J Thorac Oncol
    Hong DS et al., 2015, A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors., Oncotarget
    Sameni et al., 2016, Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models., Clin. Cancer Res.
    Goyal et al., 2017, A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma., Cancer
    Yakes et al., 2011, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth., Mol. Cancer Ther.
    Kurzrock et al., 2011, Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer., J. Clin. Oncol.
    Nakatani M et al., 2017, The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma &lt;i&gt;In Vitro&lt;/i&gt; and &lt;i&gt;In Vivo&lt;/i&gt;., Anticancer Res
    Moores et al., 2016, A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors., Cancer Res.
    Yang SP et al., 2012, Potent HGF/c-Met axis inhibitors from Eucalyptus globulus: the coupling of phloroglucinol and sesquiterpenoid is essential for the activity., J Med Chem
    Foster et al., 2015, The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models., Mol. Cancer Ther.
    Liu et al., 2014, LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth., Clin. Cancer Res.
    Larsen CA et al., 2009, Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies., J Med Chem
    Arena S et al., 2007, Genetic targeting of the kinase activity of the Met receptor in cancer cells., Proc Natl Acad Sci U S A
    Wittman MD et al., 2009, Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development., J Med Chem
  • TEPOTINIB   MET

    Interaction Score: 4.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    25736998 32469185 24061647


    Sources:
    DTC ChemblInteractions CIViC TTD

  • TIVANTINIB   MET

    Interaction Score: 3.53

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Reported Cancer Type Lung, Prostate
    Trial Name ARQ-197

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ChemblInteractions CancerCommons TTD

  • ONARTUZUMAB   MET

    Interaction Score: 3.24

    Interaction Types & Directionality:
    antibody (inhibitory)
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type esophagus adenocarcinoma
    Indication/Tumor Type gastroesophageal junction adenocarcinoma
    Response Type no benefit

    PMIDs:
    27918764 24101053 23882082 22389872


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC CancerCommons

  • SAVOLITINIB   MET

    Interaction Score: 2.94

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant
    Approval Status Preclinical - Cell culture

    PMIDs:
    28396313 28644771 25779944 27694386 31315834


    Sources:
    JAX-CKB ChemblInteractions COSMIC CIViC TTD

  • EMIBETUZUMAB   MET

    Interaction Score: 2.36

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    Approval Status Preclinical
    Indication/Tumor Type non-small cell lung carcinoma
    combination therapy Emibetuzumab + Erlotinib

    PMIDs:
    25231402 27803065


    Sources:
    JAX-CKB TTD

  • CAPMATINIB   MET

    Interaction Score: 2.36

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Indication/Tumor Type lung large cell carcinoma
    Response Type sensitive

    PMIDs:
    28396313 15494073 28783719 27694386 28765324 25971938 32877583


    Sources:
    TALC MyCancerGenome JAX-CKB ChemblInteractions COSMIC CIViC CancerCommons TTD OncoKB

  • BMS-777607   MET

    Interaction Score: 2.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type prostate cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    28396313 22286523 20515943


    Sources:
    MyCancerGenome JAX-CKB ChemblInteractions TTD

  • CRIZOTINIB   MET

    Interaction Score: 1.83

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Clinical Status preclinical
    Pathway activation
    Variant Effect gain-of-function

    PMIDs:
    12460923 11750879 9826708 25157968 10417759 1104268 17483355 22594847 31391294 25971938 26729443 25971939 26547802 23729478 25232318 25922291 27325282 21716144 22162573 21623265 22162641 28396313 28514312 15494073 26779812 21266357 26432108 26483207 27393507 27149990 27283993 27595477 27694386 27343442 28765324 28522754 31584608 31416808 26892698 31932802 31809977 30339198 10592235


    Sources:
    TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions DoCM COSMIC CIViC MyCancerGenomeClinicalTrial PharmGKB TTD OncoKB

  • TELISOTUZUMAB   MET

    Interaction Score: 1.77

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    None found


    Sources:
    JAX-CKB ChemblInteractions TTD

  • TELISOTUZUMAB VEDOTIN   MET

    Interaction Score: 1.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    27573171


    Sources:
    JAX-CKB TTD

  • EUCALYPTIN A   MET

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22934600


    Sources:
    DTC

  • MACROCARPAL B   MET

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22934600


    Sources:
    DTC

  • GALLOCATECHIN GALLATE   MET

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19839593


    Sources:
    DTC

  • MACROCARPAL A   MET

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22934600


    Sources:
    DTC

  • EMD-1204831   MET

    Interaction Score: 1.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • AMG-208   MET

    Interaction Score: 1.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    26155941


    Sources:
    ChemblInteractions

  • (-)-OLEOCANTHAL   MET

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23403296


    Sources:
    DTC

  • PF-04217903   MET

    Interaction Score: 1.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes
    Notes

    PMIDs:
    None found


    Sources:
    TALC DTC MyCancerGenome ChemblInteractions COSMIC TTD

  • JNJ-38877605   MET

    Interaction Score: 1.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • SAR-125844   MET

    Interaction Score: 1.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Indication/Tumor Type lung cancer

    PMIDs:
    25504634


    Sources:
    JAX-CKB ChemblInteractions TTD

  • TYROSOL SINAPATE   MET

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23403296


    Sources:
    DTC

  • CHEMBL261641   MET

    Interaction Score: 0.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23403296 17595299


    Sources:
    DTC

  • TAS-115   MET

    Interaction Score: 0.88

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes
    Indication/Tumor Type stomach cancer

    PMIDs:
    24140932


    Sources:
    JAX-CKB ChemblInteractions

  • OSIMERTINIB   MET

    Interaction Score: 0.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical
    Response Type resistant
    Evidence Type Actionable

    PMIDs:
    27252416 27393507 27694386 29386539


    Sources:
    JAX-CKB CIViC OncoKB

  • GOLVATINIB   MET

    Interaction Score: 0.79

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes
    Indication/Tumor Type stomach cancer

    PMIDs:
    19832844


    Sources:
    JAX-CKB ChemblInteractions TTD

  • CABOZANTINIB   MET

    Interaction Score: 0.72

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive

    PMIDs:
    28396313 27694386 26432786 28192597 25971939 21926191 21606412 29061793


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB CIViC MyCancerGenomeClinicalTrial TTD OncoKB

  • PHA-665752   MET

    Interaction Score: 0.71

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    combination therapy Gefitinib + PHA-665752
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    18077425 21266357 23542356 24165158


    Sources:
    DTC JAX-CKB

  • NAQUOTINIB   MET

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29386539


    Sources:
    CIViC

  • MK-8033   MET

    Interaction Score: 0.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • COMETRIQ   MET

    Interaction Score: 0.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma

    PMIDs:
    None found


    Sources:
    CancerCommons

  • JNJ-61186372   MET

    Interaction Score: 0.59

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    27216193


    Sources:
    JAX-CKB

  • APRATOXIN F   MET

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • BMS-698769   MET

    Interaction Score: 0.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • GLESATINIB   MET

    Interaction Score: 0.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Reported Cancer Type Lung
    Trial Name MGCD265

    PMIDs:
    15494073 27694386 28765324


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB CancerCommons

  • MERESTINIB   MET

    Interaction Score: 0.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • AMG-337   MET

    Interaction Score: 0.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SGX-523   MET

    Interaction Score: 0.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • FICLATUZUMAB   MET

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type multiple myeloma
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    24901237


    Sources:
    JAX-CKB

  • AMUVATINIB   MET

    Interaction Score: 0.5

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes
    Trial Name MP-470

    PMIDs:
    24326130


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

  • FORETINIB   MET

    Interaction Score: 0.49

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Approval Status Preclinical
    combination therapy Foretinib + Rucaparib
    Evidence Type Actionable

    PMIDs:
    26779812 23213094


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC CancerCommons TTD

  • ALTIRATINIB   MET

    Interaction Score: 0.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Approval Status Preclinical

    PMIDs:
    26285778 26965451 24362531


    Sources:
    JAX-CKB ChemblInteractions TTD

  • EPICATECHIN GALLATE   MET

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19839593


    Sources:
    DTC

  • BPI-9016   MET

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ALVESPIMYCIN   MET

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    26483207


    Sources:
    JAX-CKB

  • LY-3164530   MET

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CMX-2043   MET

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • SITRAVATINIB   MET

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CABOZANTINIB S-MALATE   MET

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BMS-794833   MET

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BMS-817378   MET

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • YUANHUADINE   MET

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21916433


    Sources:
    DTC

  • ARRY-300   MET

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MK-2461   MET

    Interaction Score: 0.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    MyCancerGenome ChemblInteractions TTD

  • GANETESPIB   MET

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    26483207


    Sources:
    JAX-CKB

  • CHEMBL399530   MET

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AFATINIB   MET

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive
    Approval Status Clinical Study

    PMIDs:
    27694386


    Sources:
    JAX-CKB

  • VELIPARIB   MET

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26779812


    Sources:
    JAX-CKB

  • CEP-11981   MET

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22148921


    Sources:
    DTC

  • MGCD-265   MET

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CRENOLANIB   MET

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenomeClinicalTrial

  • BMS-754807   MET

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19778024


    Sources:
    DTC

  • TRASTUZUMAB   MET

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type sensitive
    combination therapy Crizotinib + Trastuzumab + Paclitaxel
    combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin

    PMIDs:
    26432108 22850551


    Sources:
    JAX-CKB

  • GEFITINIB   MET

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Cell culture
    combination therapy Gefitinib + NPS-1034
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    27612490 23542356 24165158 17463250 23993328


    Sources:
    DTC JAX-CKB CIViC OncoKB

  • BEVACIZUMAB   MET

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Altiratinib + Bevacizumab
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

    PMIDs:
    25363205 26432108 26965451


    Sources:
    JAX-CKB

  • ERLOTINIB   MET

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Onartuzumab + Erlotinib
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type conflicting

    PMIDs:
    27694386 27803065 24101053


    Sources:
    DTC JAX-CKB OncoKB

  • SELUMETINIB   MET

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Selumetinib + BEZ235
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    25952648 24939055


    Sources:
    JAX-CKB CIViC

  • LAPATINIB   MET

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Crizotinib + Lapatinib
    Indication/Tumor Type esophagus adenocarcinoma
    Response Type sensitive

    PMIDs:
    26432108 27595477


    Sources:
    JAX-CKB

  • VEMURAFENIB   MET

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26359985 27325282


    Sources:
    CIViC

  • PILARALISIB   MET

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    25637314


    Sources:
    JAX-CKB

  • TRAMETINIB   MET

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy INC280 + Trametinib
    Indication/Tumor Type collecting duct carcinoma
    Response Type sensitive

    PMIDs:
    28783719 25952648


    Sources:
    JAX-CKB CIViC

  • PANITUMUMAB   MET

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy JNJ 38877605 + Panitumumab
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    23729478


    Sources:
    JAX-CKB

  • PONATINIB   MET

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung small cell carcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    25122427


    Sources:
    JAX-CKB

  • EPIGALOCATECHIN GALLATE   MET

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19839593


    Sources:
    DTC

  • OLAPARIB   MET

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26779812


    Sources:
    JAX-CKB

  • LEUCOVORIN   MET

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
    Indication/Tumor Type gastric adenocarcinoma
    Response Type resistant

    PMIDs:
    26432108


    Sources:
    JAX-CKB

  • CETUXIMAB   MET

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type sensitive
    combination therapy Cetuximab + JNJ 38877605
    Approval Status Preclinical - Cell culture

    PMIDs:
    23729478


    Sources:
    JAX-CKB CIViC

  • DACTOLISIB   MET

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    24939055


    Sources:
    DTC JAX-CKB

  • RUCAPARIB   MET

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    combination therapy Foretinib + Rucaparib
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    26779812


    Sources:
    JAX-CKB

  • CHEMBL202721   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAPECITABINE   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type resistant
    Evidence Type Actionable
    Approval Status Clinical Study

    PMIDs:
    26432108


    Sources:
    JAX-CKB

  • OXALIPLATIN   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab
    Indication/Tumor Type gastric adenocarcinoma
    Response Type resistant

    PMIDs:
    26432108


    Sources:
    JAX-CKB

  • IMATINIB   MET

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Imatinib + Carboplatin + Paclitaxel
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • CHEMBL546797   MET

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PACLITAXEL   MET

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type gastric adenocarcinoma
    combination therapy Crizotinib + Trastuzumab + Paclitaxel
    Evidence Type Actionable

    PMIDs:
    26432108 28514312


    Sources:
    JAX-CKB

  • DASATINIB   MET

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    26483207


    Sources:
    JAX-CKB

  • CHEMBL541400   MET

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CARBOPLATIN   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Imatinib + Carboplatin + Paclitaxel
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • SORAFENIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Sorafenib
    Indication/Tumor Type gastrointestinal stromal tumor
    Response Type sensitive

    PMIDs:
    25363205


    Sources:
    JAX-CKB

  • PAZOPANIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL1997335   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SNS-314   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OSI-632   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • JNJ-7706621   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PD-0166285   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FLUOROURACIL   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
    Indication/Tumor Type gastric adenocarcinoma
    Response Type resistant

    PMIDs:
    26432108


    Sources:
    JAX-CKB

  • ENTRECTINIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LINIFANIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • R-406   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SP-600125   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CYC-116   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TAE-684   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PF-00562271   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ILORASERTIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CENISERTIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Ensembl: ENSG00000105976

    • Version: 101_38

    Alternate Names:
    MET Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P08581

    • Version: January-2014

    Alternate Names:
    MET Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass EC:2.7.10.1

    Publications:

  • CancerCommons: MET

    • Version: 25-July-2013

    Alternate Names:
    4233 Entrez Gene ID

    Gene Info:
    CancerCommons Reported Gene Name MET
    CancerCommons Reported Gene Name MET, VEGFRs, Axl, Tie2, Ron

    Publications:

  • BaderLabGenes: MET

    • Version: February-2014

    Alternate Names:
    4233 Entrez Gene ID

    Gene Info:
    Initial Gene Query MET
    Counted Citations from 1950-2000 4560

    Gene Categories:
    KINASE

    Publications:

  • HopkinsGroom: P08581

    • Version: 11-September-2012

    Alternate Names:
    MET_HUMAN Uniprot Id
    4233 Entrez Gene Id
    P08581 Uniprot Accession

    Gene Info:
    Human Readable Name KINASE
    Interpro Type Domain
    Uniprot Evidence 1: Evidence at protein level

    Gene Categories:
    KINASE, DRUGGABLE GENOME

    Publications:

  • RussLampel: ENSG00000105976

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000105976 Ensembl Gene Id
    MET Display Id
    HEPATOCYTE GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (MET PROTO- ONCOGENE TYROSINE KINASE) (C-MET) (HGF RECEPTOR) (HGF-SF RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P08581] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • JAX-CKB: MET

    • Version: 27-September-2017

    Alternate Names:
    4233 CKB Entrez Id
    MET CKB Gene Synonym
    AUTS9 CKB Gene Synonym

    Gene Info:

    Publications:
    Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
    Bardelli et al., 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer., Cancer Discov
    Engelman et al., 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling., Science

  • PharmGKB: MET

    • Version: 18-August-2020

    Alternate Names:
    PA30763 PharmGKB ID

    Gene Info:

    Publications:
    Ou SH, 2011, Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond., Drug Des Devel Ther

  • CIViC: MET

    • Version: 14-September-2020

    Alternate Names:
    4233 Entrez Gene ID
    52 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:
    Bardelli et al., 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer., Cancer Discov
    Lee J et al., 2019, Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial., Cancer Discov
    Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov

  • DoCM: MET

    • Version: 27-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Lorenzato et al., 2002, Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion., Cancer Res.
    Bardelli et al., 1998, Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth., Proc. Natl. Acad. Sci. U.S.A.
    Dalinka et al., 1975, The radiology of osseous and articular infection., CRC Crit Rev Clin Radiol Nucl Med

  • DTC: MET

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    McDermott U et al., 2007, Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling., Proc Natl Acad Sci U S A
    Yang SP et al., 2012, Potent HGF/c-Met axis inhibitors from Eucalyptus globulus: the coupling of phloroglucinol and sesquiterpenoid is essential for the activity., J Med Chem
    Dorsch D et al., 2015, Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors., Bioorg Med Chem Lett

  • TALC: MET

    • Version: 12-May-2016

    Alternate Names:
    MET Gene Symbol

    Gene Info:

    Publications:

  • TALC: HGFR

    • Version: 12-May-2016

    Alternate Names:
    HGFR Gene Symbol

    Gene Info:

    Publications:

  • MyCancerGenome: MET

    • Version: 20-Jun-2017

    Alternate Names:
    4233 Entrez Gene Id
    MET MyCancerGenome Gene Symbol
    MET MyCancerGenome Reported Gene Name

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000105976

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000105976 Gene Symbol
    MET Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TALC: C-MET

    • Version: 12-May-2016

    Alternate Names:
    C-MET Gene Symbol

    Gene Info:

    Publications:

  • ChemblInteractions: MET

    • Version: chembl_23

    Alternate Names:
    MET GENE_SYMBOL
    Hepatocyte growth factor receptor UNIPROT
    HGF/SF receptor UNIPROT

    Gene Info:

    Publications:

  • OncoKB: MET

    • Version: 23-July-2020

    Alternate Names:
    4233 OncoKB Entrez Id
    RCCP2 OncoKB Gene Synonym
    HGFR OncoKB Gene Synonym

    Gene Info:

    Publications:

  • Tempus: MET

    • Version: 11-November-2018

    Alternate Names:
    MET Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • dGene: MET

    • Version: 27-Jun-2013

    Alternate Names:
    4233 Gene ID
    AUTS9 dGene Synonym
    HGFR dGene Synonym

    Gene Info:

    Gene Categories:
    KINASE, TYROSINE KINASE

    Publications:

  • TTD: Proto-oncogene c-Met

    • Version: 2020.06.01

    Alternate Names:
    MET TTD Gene Abbreviation
    T40474 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: MET

    • Version: 01-February-2022

    Alternate Names:
    Hepatocyte growth factor receptor Gene Name
    P08581 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE

    Publications:

  • MyCancerGenomeClinicalTrial: MET

    • Version: 30-February-2014

    Alternate Names:

    Gene Info:

    Publications:

  • MskImpact: MET

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • ClearityFoundationBiomarkers: MET

    • Version: 26-July-2013

    Alternate Names:

    Gene Info:

    Publications:

  • ClearityFoundationClinicalTrial: MET

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • ClearityFoundationClinicalTrial: C-MET

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • FoundationOneGenes: MET

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: MET

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • GO: MET

    • Version: 01-February-2022

    Alternate Names:

    Gene Info:

    Gene Categories:
    CELL SURFACE, TYROSINE KINASE

    Publications:

  • Oncomine: MET

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • COSMIC: MET

    • Version: 4-Sep-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21